Ozempic Settlement Calculator 2026: Estimate Potential Claim Value
Use the Ozempic Settlement Calculator to organise GLP-1 prescription history, the injury alleged, treatment records, medical expenses and the evidence behind a gastroparesis or intestinal obstruction claim.
- Organises which GLP-1 drug was taken, when, and for how long.
- Captures the injury alleged — gastroparesis, ileus, obstruction or pancreatitis.
- Helps identify missing pharmacy, gastroenterology and imaging records.
- Makes clear that the expert rulings, not a settlement, are the next milestone.
Get Your Ozempic Claim Estimate
Answer the guided questions using the most accurate prescription, diagnosis, treatment and damages information available.
Is the calculator estimate what I would receive?
No. It is a gross figure, and no GLP-1 settlement exists to be paid from. Attorney fees, case expenses and lien repayment would all come out of any eventual allocation.
Should I wait for the expert rulings before filing?
Waiting has a cost. The summary judgment and Daubert rulings will shape the litigation, but they do not pause any state limitation period, and for early GLP-1 users those periods may already be running short.
How the Ozempic Settlement Calculator Works
The calculator organises the facts most likely to matter in an initial claim review. Because no settlement matrix exists, its output is a structured summary of your position rather than a prediction of any payout.
1. Record the Prescription
Enter which GLP-1 drug was taken — Ozempic, Wegovy, Mounjaro, Zepbound or another — with dates and dosage.
2. Enter the Diagnosis
Gastroparesis, ileus, intestinal obstruction, acute pancreatitis or another gastrointestinal injury, with the test that confirmed it.
3. Add Treatment History
Hospital admissions, feeding tubes, surgery, ongoing symptom management and medication.
4. Review What Is Missing
The output highlights the pharmacy, gastroenterology and imaging records an attorney will ask for.
Factors That Can Affect Ozempic Settlement Value
Because no settlement matrix has been published, these are the factors comparable pharmaceutical litigation suggests will drive value.
Diagnostic confirmation
A gastric emptying study confirming gastroparesis, or imaging confirming obstruction, is far stronger than a symptom-based diagnosis.
Duration of use before injury
How long the drug was taken before symptoms began, and whether they persisted after discontinuation.
Severity and permanence
Hospitalisation, feeding tube dependence, surgery and permanent gastric dysfunction sit well above transient nausea.
Pre-existing conditions
Diabetes independently causes gastroparesis, and this will be the central defence argument in many claims.
Which drug and manufacturer
Novo Nordisk and Eli Lilly products are both in the litigation, with different labels and different warning histories.
Economic loss
Hospital costs, ongoing treatment, lost earnings and future care needs.
Evidence That Can Support a Ozempic Claim
These claims turn on objective diagnostic confirmation. Symptoms alone, however severe, are difficult to distinguish from the many other causes of gastrointestinal dysfunction.
Pharmacy Records
Prescription fills for the GLP-1 drug, with dates, dosage and duration.
Pharmacies can usually retrieve several years of dispensing history.Gastric Emptying Study
The objective test that confirms gastroparesis, and the strongest single document in most of these claims.
Held by the gastroenterology practice or hospital that ordered it.Imaging and Endoscopy
Scans or endoscopic findings documenting ileus, obstruction or inflammation.
Requested from the treating hospital.Hospital Records
Admissions, emergency presentations, surgery and feeding tube placement.
Requested from each admitting hospital.Pre-Treatment Baseline
Records establishing gastrointestinal function before the drug was started, particularly for diabetic claimants.
Essential, because diabetes independently causes gastroparesis.Damages Documentation
Medical bills, insurance statements, lost earnings and future care costs.
Assembled from providers, insurers and employers.Where GLP-1 Litigation Stands in 2026
MDL 3094 consolidates claims that Novo Nordisk and Eli Lilly failed to warn adequately about severe gastrointestinal effects of GLP-1 receptor agonists. It is now at its decisive procedural stage.
Bellwether selection was expected around mid-2026 with first trials possible in late 2026, but that timetable depends entirely on how the expert rulings land. Until they do, no responsible source can put a number on an individual claim.
Ozempic Lawsuit Filing Deadlines
Limitation periods for pharmaceutical injury claims vary by state and generally run from the date of injury, or from the point at which the connection between the injury and the drug could reasonably have been discovered.
Because GLP-1 drugs have been widely prescribed since 2017 and gastrointestinal symptoms often develop gradually, the discovery point is frequently disputed. In shorter-limitation states, deadlines for early users may already have run.
The pending expert rulings do not pause any state deadline. Waiting for the outcome before filing is a strategy with a real cost.
Ozempic Lawsuit, Settlement & Related Claim Resources
Why the Estimate Is Not the Cheque
Any figure this calculator produces, and any figure quoted in a news headline, is a gross number. Several deductions sit between a gross allocation and the money that reaches a claimant, and they are the same in every mass tort.
1. Gross allocation
What the claim is valued at, before anything is taken out.
2. Attorney fees and costs
The contingency fee plus case expenses, set out in the retainer agreement you sign at the start.
3. Liens and reimbursements
Health insurers and Medicare are repaid for hospital admissions, procedures and ongoing treatment they funded.
4. Net to claimant
What remains after fees, costs and lien resolution — and what actually arrives.
Lien resolution is usually the step that takes longest. Health insurers, and in many cases Medicare or Medicaid, have a right to be reimbursed out of a settlement for treatment they already paid for. Those amounts can frequently be reduced through a formal resolution process, but the process adds time — often months between an agreed figure and a distributed payment.
None of this is a reason not to bring a claim. It is a reason to read every Ozempic figure you encounter as a gross number rather than a net one, and to ask about the fee structure and likely lien exposure early rather than late.
Ozempic Settlement Calculator FAQ
How does the Ozempic settlement calculator work?
It organises prescription history, the injury alleged, treatment and damages into an educational summary. Because no settlement matrix exists, it cannot predict a payout.
What is the average Ozempic settlement?
There is none. As of August 2026 no settlements have been announced and no case has been tried to verdict in MDL 3094.
What is the next milestone in this litigation?
The summary judgment and Daubert rulings. Briefing ran through July 2026, and those decisions determine whether the plaintiffs’ general causation evidence is admissible and the cases can reach a jury.
I have diabetes. Does that mean I cannot claim?
Not necessarily, but it is the central issue. Diabetes independently causes gastroparesis, so records establishing your gastrointestinal function before the drug was started matter a great deal.
What about vision loss claims?
NAION vision loss claims were separated into their own proceeding, MDL 3163, and are not part of MDL 3094. They are on a different track with a different timetable.
Does the calculator submit a claim?
No. It produces an educational summary and, if you choose, passes your details for a free case review. It does not file anything and creates no attorney-client relationship.
Request a Free Ozempic Case Review
If you took Ozempic, Wegovy, Mounjaro or another GLP-1 drug and were diagnosed with gastroparesis, intestinal obstruction or acute pancreatitis, use the calculator to organise the records or request a confidential review.
Sources and Further Reading
JPML — Pending MDL Dockets
Official report listing 3,928 actions pending in MDL 3094 as of 3 August 2026.
View the JPML reportU.S. District Court, Eastern District of Pennsylvania
The court administering MDL 3094 before Judge Karen S. Marston.
View the courtFDA — GLP-1 Receptor Agonist Safety
Federal regulatory background on GLP-1 drugs and reported gastrointestinal adverse events.
View the FDA pageNIH — Gastroparesis
Clinical background on gastroparesis, its diagnosis and its other causes.
View the NIH pageMDL Update — MDL 3094
Docket tracker covering pending counts, expert briefing and the bellwether timetable.
View the tracker
